Please login to the form below

Not currently logged in

CHMP backs Xolair for severe hives

Novartis set to expand indications for asthma drug
Novartis building

Novartis has taken a step towards expanding the indications for its severe asthma drug Xolair after it was recommended for EU approval to treat a skin disease.

The Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on Xolair (omalizumab) for a chronic and debilitating form of hives known as chronic spontaneous urticaria (CSU).

Based on the results of a phase III trial the drug has been backed to treat CSU as a monthly subcutaneous injection in patients aged over 12 as an add-on to standard treatment with antihistamines and – in severe cases - corticosteroids. Around half of all CSU patients do not respond even to high-dose antihistamine therapy.

As an asthma therapy Xolair has steadily grown to become a major product for Novartis, with sales rising 20 per cent to $440m in the first nine months of 2013, and the addition of CSU could help usher the drug into blockbuster territory.

Chronic urticaria affects around 1 per cent of the world's population, and CSU accounts for around two-thirds of patients, and Novartis estimates that 1.6 million people are diagnosed in the US and EU alone, with around 70,000 refractory to all available therapies.

“If approved, Xolair will be the first and only licensed therapy in the EU for up to 50 per cent of CSU patients not responding to approved doses of antihistamines,” commented Tim Wright, global head of development at Novartis' pharmaceuticals division.

Novartis has said it sees particular promise in immunological therapies for skin disease, and indicated recently that Xolair and its psoriasis candidate secukinumab could collectively provide peak sales of $2bn-$3bn a year.

David Epstein, head of pharmaceuticals at Novartis, described CSU in graphic terms at an investor presentation last year.

“The attacks … can result in sloughing in the skin, hives, itching, sometimes eyes that are shut, lips that are swollen, loss of airway [and the] ability to breathe,” said Epstein. “CSU leaves patients in constant fear of when the next attack is going to occur,” he added.

Article by
Thomas Meek

24th January 2014

From: Sales



COVID-19 Updates and Daily News

Featured jobs


Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

The disparity of patient experiences with Crohn’s Disease in Europe and Japan...
Patient diversity in clinical trials
The pursuit of patient diversity in clinical trials
When all-inclusive isn’t an option, it’s an obligation...
Overcoming the digital patient recruitment challenges of connecting with patients
How many irrelevant experiences, ads, emails, direct messages have you rejected this week?...